Adam Feuerstein on Muck Rack

Adam Feuerstein Verified

As seen in:  The Street

Sr. Columnist at TheStreet, aka the Col. Jessup of biotech/drug stocks. Data Are. I curse. Said one analyst: The likes of Adam Feuerstein attack viciously.

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

thestreet.com — I've made my share of screw-ups when it comes to predicting the future of Sarepta and Prosensa. My track record isn't great, despite my best efforts. The scenario I describe above seems plausible to me, but my confidence level is low so tell me if you agree. What, if anything, am I missing?

Biotech Stock Mailbag: Prosensa, Sarepta, Arena Pharma, Hemispherx

thestreet.com — BOSTON (TheStreet) -- Welcome back to this week's Biotech Stock Mailbag. @adamfeuerstein any thoughts on rna after the debacle with srpt? - Joe Smith (@zwerp2000) October 27, 2014 I'm assuming Prosensa completes the submission of the drisapersen data package to the FDA by the end of the year.

Aegerion Problems Mount With Poor Quarter and Reduced Guidance

thestreet.com — CAMBRIDGE ( TheStreet) -- The accusations of cocaine use and having sex with someone else's wife are the least of Marc Beer's problems. Aegerion Pharmaceuticals , the company he runs as CEO, is falling apart. Shares are down 28% to $24.45 in Thursday's after-market trading session.

Aegerion Board Expresses Support for Embattled CEO Amid Drug Use Accusations

thestreet.com — Stocks in this article: AEGR NEW YORK ( TheStreet) -- Aegerion Pharmaceuticals issued a statement Tuesday night expressing its board of directors' support for CEO Marc Beer in the face of accusations of cocaine use and extramarital sex involving a Jefferies investment banker and his wife. "Marc categorically denies the allegations.

Sarepta Shares Falls on Duchenne Drug Approval Filing Delay

thestreet.com — CAMBRIDGE (TheStreet) -- Sarepta Therapeutics is delaying the filing of an FDA approval application for its Duchenne muscular dystrophy drug eteplirsen until the middle of next year because regulators have asked for a slew of new data, the company said Monday. Sarepta previously promised -- and investors expected -- eteplirsen's approval filing in December.

Aegerion, Seattle Genetics CEOs Accused in Suit of Cocaine Use

thestreet.com — NEW YORK ( TheStreet) -- An ugly divorce case pitting a Jefferies & Co. health care investment banker against his estranged wife has ensnared the CEOs of Aegerion Pharmaceuticals and Seattle Genetics in allegations of illicit drug use and extramarital sex romps.

Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta

thestreet.com — BOSTON ( TheStreet) -- This week's Biotech Stock Mailbag opens with Rockwell Medical . Stuart A. writes: " Adam, Rockwell Medical has an FDA advisory committee meeting coming up soon. Can you talk about the issues that might be raised there?" The Food and Drug Administration is convening an advisory panel on Nov.

Alcobra Applies Revisionist History to ADHD Drug Study Analysis

thestreet.com — TEL AVIV, Israel ( TheStreet) -- Alcobra disclosed in a regulatory filing Wednesday night new details about the phase III study of attention-deficit hyperactivity disorder drug candidate MDX which contradict results announced by the company in an Oct. 6 press release.

Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results

thestreet.com — A single injection of a microRNA therapeutic directed at a genetic target in the liver of hepatitis C patients produced a significant drop in viral load, according to interim results from an early-stage study announced Wednesday by Regulus Therapeutics , the developer of the therapy, known as RG-101.

Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results

thestreet.com — Yesterday afternoon, I posed the following question about Achillion Pharmaceuticals and its hepatitis C "nuc" ACH-3422 to the biotech Twitter-verse: For those not obsessed with the clinical development of hepatitis C drugs (what's wrong with you?) -- My question refers to the imminent announcement of results from a phase I "proof of concept" study of '3422 in treatment-naive genotype 1 patients.
More Articles →
Oct 31, 2014

@BioRunUp I ordered a magnum sized bottle of Curieux for Thanksgiving dinner.

Oct 31, 2014

@BioRunUp did u like the Allagash Curieux? I'm not even gonna ask about that bottle or grain alcohol.

Oct 31, 2014

@TroKalayjianCRG Tro -- one word of advice re: what to do with Dr. delusionalMNKD: Block.

Oct 31, 2014

RT @ivanoransky: The @Cubs statement on manager Rick Renteria's firing is a model of painful transparency m.cubs.mlb.com/news/article/1…

Oct 31, 2014

@ericjackson Or, in someone else’s wife. Oh no, I didn’t just tweet that…

Oct 31, 2014

@DamianFierce Jefferies “puts client first.” Yup. You can have sex with my wife first, no problem!!

Learn how to connect with Adam on social media by joining Muck Rack Pro



Are You a Journalist?

Make a Portfolio

Create a free Muck Rack account to customize your profile and upload a portfolio of your best work.


Share This Profile